Osteocyte Control of Osteoclastogenesis

Overview

Journal Bone

Specialties Endocrinology
Orthopedics

Date 2012 Sep 4

PMID 22939943

Citations 112

Authors

Charles A OBrien

Tomoki Nakashima

Hiroshi Takayanagi

Affiliations

Soon will be listed here.

Abstract

Multiple lines of evidence support the idea that osteocytes act as mechanosensors in bone and that they control bone formation, in part, by expressing the Wnt antagonist sclerostin. However, the role of osteocytes in the control of bone resorption has been less clear. Recent studies have demonstrated that osteocytes are the major source of the cytokine RANKL involved in osteoclast formation in cancellous bone. The goal of this review is to discuss these and other studies that reveal mechanisms whereby osteocytes control osteoclast formation and thus bone resorption.

Citing Articles

PTH receptor signalling, osteocytes and bone disease induced by diabetes mellitus.

Marino S, Bellido T Nat Rev Endocrinol. 2024; 20(11):661-672.

PMID: 39020007 DOI: 10.1038/s41574-024-01014-7.

Unraveling the relationship between serum parathyroid hormone levels and trabecular bone score: a cross-sectional study.

Zhao T, Li Y, Tian J, Kang Y, Xu J, Shao H Sci Rep. 2024; 14(1):13065.

PMID: 38844829 PMC: 11156926. DOI: 10.1038/s41598-024-63979-9.

Periparturient Mineral Metabolism: Implications to Health and Productivity.

Vieira-Neto A, Lean I, Santos J Animals (Basel). 2024; 14(8).

PMID: 38672379 PMC: 11047658. DOI: 10.3390/ani14081232.

Signaling pathways of dental implants' osseointegration: a narrative review on two of the most relevant; NF-κB and Wnt pathways.

Emam S, Moussa N BDJ Open. 2024; 10(1):29.

PMID: 38580623 PMC: 10997788. DOI: 10.1038/s41405-024-00211-w.

Connexin 43 in the function and homeostasis of osteocytes: a narrative review.

Ma L, Wang W, Xu G, Li H, Liu F, Shao H Ann Jt. 2024; 9:10.

PMID: 38529291 PMC: 10929443. DOI: 10.21037/aoj-23-65.

References

Gu G, Nars M, Hentunen T, Metsikko K, Vaananen H . Isolated primary osteocytes express functional gap junctions in vitro. Cell Tissue Res. 2005; 323(2):263-71. DOI: 10.1007/s00441-005-0066-3. View

Kogianni G, Mann V, Noble B . Apoptotic bodies convey activity capable of initiating osteoclastogenesis and localized bone destruction. J Bone Miner Res. 2008; 23(6):915-27. DOI: 10.1359/jbmr.080207. View

Robling A, Niziolek P, Baldridge L, Condon K, Allen M, Alam I . Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem. 2007; 283(9):5866-75. DOI: 10.1074/jbc.M705092200. View

Shinohara M, Koga T, Okamoto K, Sakaguchi S, Arai K, Yasuda H . Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell. 2008; 132(5):794-806. DOI: 10.1016/j.cell.2007.12.037. View

Aliprantis A, Ueki Y, Sulyanto R, Park A, Sigrist K, Sharma S . NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest. 2008; 118(11):3775-89. PMC: 2564610. DOI: 10.1172/JCI35711. View

Li X, Ominsky M, Stolina M, Warmington K, Geng Z, Niu Q . Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Bone. 2009; 45(4):669-76. DOI: 10.1016/j.bone.2009.06.011. View

Staehling-Hampton K, Proll S, Paeper B, Zhao L, Charmley P, Brown A . A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002; 110(2):144-52. DOI: 10.1002/ajmg.10401. View

Ke H, Richards W, Li X, Ominsky M . Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev. 2012; 33(5):747-83. DOI: 10.1210/er.2011-1060. View

Boyle W, Simonet W, Lacey D . Osteoclast differentiation and activation. Nature. 2003; 423(6937):337-42. DOI: 10.1038/nature01658. View

10.

Barrow A, Raynal N, Andersen T, Slatter D, Bihan D, Pugh N . OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice. J Clin Invest. 2011; 121(9):3505-16. PMC: 3163954. DOI: 10.1172/JCI45913. View

11.

Ueno Y, Shinki T, Nagai Y, Murayama H, Fujii K, Suda T . In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. J Cell Biochem. 2003; 90(2):267-77. DOI: 10.1002/jcb.10623. View

12.

Martin-Millan M, Almeida M, Ambrogini E, Han L, Zhao H, Weinstein R . The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol. 2010; 24(2):323-34. PMC: 2817608. DOI: 10.1210/me.2009-0354. View

13.

Miao D, Li J, Xue Y, Su H, Karaplis A, Goltzman D . Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice. Endocrinology. 2004; 145(8):3554-62. DOI: 10.1210/en.2003-1695. View

14.

Kong Y, Yoshida H, Sarosi I, Tan H, Timms E, Capparelli C . OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999; 397(6717):315-23. DOI: 10.1038/16852. View

15.

Zhang M, Xuan S, Bouxsein M, von Stechow D, Akeno N, Faugere M . Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem. 2002; 277(46):44005-12. DOI: 10.1074/jbc.M208265200. View

16.

Lomaga M, Yeh W, Sarosi I, Duncan G, Furlonger C, Ho A . TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 1999; 13(8):1015-24. PMC: 316636. DOI: 10.1101/gad.13.8.1015. View

17.

Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H . Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002; 3(6):889-901. DOI: 10.1016/s1534-5807(02)00369-6. View

18.

Kim S, Yamazaki M, Zella L, Shevde N, Pike J . Activation of receptor activator of NF-kappaB ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long-range enhancers. Mol Cell Biol. 2006; 26(17):6469-86. PMC: 1592822. DOI: 10.1128/MCB.00353-06. View

19.

Simonet W, Lacey D, Dunstan C, Kelley M, Chang M, Luthy R . Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89(2):309-19. DOI: 10.1016/s0092-8674(00)80209-3. View

20.

Rhee Y, Allen M, Condon K, Lezcano V, Ronda A, Galli C . PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. J Bone Miner Res. 2010; 26(5):1035-46. PMC: 3179307. DOI: 10.1002/jbmr.304. View